您好,欢迎访问中山大学肿瘤防治中心官方网站!
内部网 职工邮箱 图书馆 OA系统 医生门户 English
院士风采 首席专家 临床专家 科研学者 客座教授 人才名录 护理专家
首页
  • 曾木圣

    职务:中心副主任、副院长
    职称:博士、教育部“长江学者”特聘教授、博士生导师,华南肿瘤学国家重点实验室肿瘤病毒与生物标记研究室PI
    专长:恶性肿瘤发病机制、早期诊断和预后研究
    姓名: 曾木圣
    职称: 博士、研究员、博士生导师、华南肿瘤学国家重点实验室肿瘤病毒与生物标记研究室PI
    职务: 中心副主任、副院长
    专长: 恶性肿瘤发病机制、早期诊断和预后研究

      2003年回国后被中山大学肿瘤防治中心聘为副研究员,组建肿瘤病毒学和肿瘤分子标志研究组;2006年聘为研究员,博士生导师,入选2006年“教育部新世纪优秀人才计划”; 2010入选广东省“千百十人才国家级培养对象”,并获得2010年“国家杰出青年科学基金”项目资助,2014年被聘为教育部“长江学者”特聘教授;2016年入选广东省培养高层次人才特殊支持计划“杰出人才”(南粤百杰)。现任中山大学肿瘤防治中心副主任、副院长,中国抗癌协会理事,广东省抗癌协会第四届理事会常务理事、秘书长,中国抗癌协会肿瘤标志专业委员会副主任委员,广东省抗癌协会转移委员会主任委员。

    学科:1)肿瘤学,2)生物化学与分子生物学
    专业特长:恶性肿瘤发病机制、早期诊断和预后研究
    研究方向:1. 肿瘤病毒感染、致癌及免疫调控机制
         2. 恶性肿瘤分子标志及早期诊断
         3. 分子影像及靶向治疗

    联系电话:020-87343191;(Fax):020-87342021, Email: zengmsh@sysucc.org.cn
    通讯地址:广州市东风东路651号 中山大学肿瘤防治中心实验研究部 邮编 510060

    【教育背景】
      1988年毕业于江西医学院抚州分院(现南昌大学抚州医学分院)
      1994年毕业于中山大学(原中山医科大学),获肿瘤学硕士学位
      1998年毕业于中山大学(原中山医科大学),获微生物学博士学位。

    【留学经历】
      1999-2000年美国田纳西州立大学生物系(Tennessee State University)博士后,从事维甲酸在细胞发育及分化中作用的研究
      2000-2003年美国波士顿塔夫茨大学—新英格兰医学中心(Tufts University-New England Medical Center)肿瘤生物学实验室从事乳腺癌发病机理、诊断及预后指标的研究。
    姓名: 曾木圣
    职称: 博士、研究员、博士生导师、华南肿瘤学国家重点实验室肿瘤病毒与生物标记研究室PI
    职务: 中心副主任、副院长
    专长: 恶性肿瘤发病机制、早期诊断和预后研究

      2003年回国后被中山大学肿瘤防治中心聘为副研究员,组建肿瘤病毒学和肿瘤分子标志研究组;2006年聘为研究员,博士生导师,入选2006年“教育部新世纪优秀人才计划”; 2010入选广东省“千百十人才国家级培养对象”,并获得2010年“国家杰出青年科学基金”项目资助,2014年被聘为教育部“长江学者”特聘教授;2016年入选广东省培养高层次人才特殊支持计划“杰出人才”(南粤百杰)。现任中山大学肿瘤防治中心副主任、副院长,中国抗癌协会理事,广东省抗癌协会第四届理事会常务理事、秘书长,中国抗癌协会肿瘤标志专业委员会副主任委员,广东省抗癌协会转移委员会主任委员。

    学科:1)肿瘤学,2)生物化学与分子生物学
    专业特长:恶性肿瘤发病机制、早期诊断和预后研究
    研究方向:1. 肿瘤病毒感染、致癌及免疫调控机制
         2. 恶性肿瘤分子标志及早期诊断
         3. 分子影像及靶向治疗

    联系电话:020-87343191;(Fax):020-87342021, Email: zengmsh@sysucc.org.cn
    通讯地址:广州市东风东路651号 中山大学肿瘤防治中心实验研究部 邮编 510060

    【教育背景】
      1988年毕业于江西医学院抚州分院(现南昌大学抚州医学分院)
      1994年毕业于中山大学(原中山医科大学),获肿瘤学硕士学位
      1998年毕业于中山大学(原中山医科大学),获微生物学博士学位。

    【留学经历】
      1999-2000年美国田纳西州立大学生物系(Tennessee State University)博士后,从事维甲酸在细胞发育及分化中作用的研究
      2000-2003年美国波士顿塔夫茨大学—新英格兰医学中心(Tufts University-New England Medical Center)肿瘤生物学实验室从事乳腺癌发病机理、诊断及预后指标的研究。

    【科研成就】
      回国后组建肿瘤病毒学和肿瘤分子标志研究组,首次完成鼻咽癌相关EBV全序列分析,发现鼻咽癌相关的EBV序列特征【J Virol 2005,入选第一届中国百篇最具影响优秀国际学术论文(科技部直属中国科学技术信息研究所评选)】,提出并初步证实高发区NPC相关EBV亚型的假设;首次通过大样本流行病学调查揭示吸烟可以通过激活EBV参与鼻咽癌发病的新机制;发现EBV-LMP2A通过诱导上皮间质转化和肿瘤启动细胞群体参与NPC发生发展的新机制;发现EBV可以诱导原癌基因Bmi-1的表达,阐明Bmi-1在鼻咽上皮细胞早期转化和NPC侵袭和转移中的作用,揭示PTEN/PI3K/Akt/Snail通路介导Bmi-1诱导上皮间质转化和肿瘤转移的新机制;并建立首个单一原癌基因诱导的鼻咽上皮细胞永生化模型和EBV高效感染上皮细胞的体外模型,鉴定出EBV感染上皮细胞的关键受体或因子(NRP1、MHC-IIA、EphA2等),多方面阐明EBV进入鼻咽上皮细胞的机制;近年来利用高通量测序技术深入探索头颈肿瘤的发病机理,揭示了食管鳞状上皮细胞癌的癌前病变的基因组特征及其与肿瘤的演化发展关系,同时首次明确了鼻咽癌和头颈肿瘤中融合基因RARS-MAD1L1的发生率及作用机制。至2017止,作为课题主持人获得国家自然科学基金12项(包括重点项目2项)、国家重点研发计划、“863”课题及“973”课题各1项。发表SCI收录论文70余篇,包括国际上具有较高影响的专业性杂志Nature Communications, Nature Microbiology, PNAS, J Clin Invest, J Natl Cancer Inst, PLoS Pathogens, Cancer Research, Clinical Cancer Research, cell research, Journal of Virology, J Biol Chem等,单篇最高IF 16.6。

    【主持的主要科研项目】
    1.国家重点研发计划项目负责人“基于基因组不稳定性的新型蛋白质机器在肿瘤发生发展中的作用、机制及干预”2017-2022 1883万元
    2.国家重点研发计划子课题参与人“疱疹病毒感染与致病过程中蛋白质机器的功能机制”2016-2021 449.6万元
    3.国家自然科学基金国际(地区)合作与交流项目,81520108022,EB病毒进入鼻咽上皮细胞受体鉴定及感染机制,2016-2020年,235万元
    4.教育部“长江学者”特聘教授 2015-2019年 200万元
    5.国家自然科学基金重大研究计划(91440106)RNA结合蛋白RBM24调控miR-25-3p及lncRNA MALAT1抑制鼻咽癌的机制2015-2017年 100 万元
    6.国家自然科学基金重点项目(81230045)融合基因AARS-MADx诱导基因组不稳定性及参与鼻咽癌发生的机制 2013-2017年 280 万元
    7.“973”课题:“致瘤病毒感染和致癌机制”,2011-2017年 170 万元
    8.国家自然科学基金杰出青年基金(81025014)头颈肿瘤 2011-2014年 200 万元
    9.国家自然科学基金重点项目(30630068) 鼻咽癌早期诊断的基础研究 2007-2010年140万元  
    10.“863”计划课题(2007AA02Z477)鼻咽癌早期诊断新方法研究 2007-2010年 230万元

    【代表性论著】(*通信作者)
    1)Zhang H, Li Y, Wang HB, Zhang A, Chen ML, Fang ZX, Dong XD, Li SB, Du Y, Xiong D, He JY, Li MZ, Liu YM, Zhou AJ, Zhong Q, Zeng YX, Kieff E, Zhang ZQ, Gewurz BE, Zhao B*, Zeng MS*, Ephrin receptor A2 is an epithelial cell receptor for EBV entry. Nat Microbiol, 2017. (In Press)
    2)Zhong Q, Liu Z, Lin ZR, Hu ZD, Yuan L, Liu YM, Zhou AJ, Xu LH, Hu LJ, Wang ZF, Guan XY, Hao JJ, Lui VWY, Guo L, Mai HQ, Chen MY, Han F, Xia YF, Grandis JR, Zhang X*, Zeng MS*, The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res, 2017. 
    3)Xing J, Zhang A, Zhang H, Wang J, Li XC, Zeng MS*, Zhang Z*, TRIM29 promotes DNA virus infections by inhibiting innate immune response. Nat Commun, 2017. 8(1): p. 945 
    4)Chen XX, Zhong Q, Liu Y, Yan SM, Chen ZH, Jin SZ, Xia TL, Li RY, Zhou AJ, Su Z, Huang YH, Huang QT, Huang LY, Zhang X, Zhao YN, Yun JP, Wu QL, Lin DX, Bai F*, Zeng MS*, Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing. Nat Commun, 2017. 8(1): p. 524. 
    5)Tang LQ, Zhang H, Li Y, Zhang A, Chen ML, Li SB, Mai HQ*, Zeng MS*, A Sponsored Supplement to Science:Precision medicine in China,Chapter 2, Precision medicine for nasopharyngeal carcinoma, Science, 2016.12.23, 24~27
    6)Hua WF, Zhong Q, Xia TL, Chen Q, Zhang MY, Zhou AJ, Tu ZW, Qu C, Li MZ, Xia YF, Wang HY, Xie D, Claret FX, Song EW, Zeng MS*, RBM24 suppresses cancer progression by upregulating miR-25 to target MALAT1 in nasopharyngeal carcinoma. Cell Death Dis, 2016. 7(9): p. e2352 
    7)Hu LJ, Lin ZR, Wu YH, Dong JQ, Zhao B, Cheng YB, Huang PY, Xu LH, Xia TL, Xiong D, Wang HB, Li MZ, Guo L, Kieff E, Zeng YX, Zhong Q*, Zeng MS*, Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing. Front Med, 2016. 10(1): p. 61-75.
    8)Li RC, Du Y, Zeng QY, Tang LQ, Zhang H, Li Y, Liu WL, Zhong Q, Zeng MS*, Huang XM*, Antibodies Against Epstein-Barr Virus Glycoprotein gp42 for the Diagnosis of Nasopharyngeal Carcinoma. Clin Lab, 2016. 62(4): p. 553-61.
    9)Tang LQ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Zhang L, Guo SS, Liu LT, Guo L, Wu YS, Luo DH, Huang PY, Mo HY, Xiang YQ, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Cao KJ, Qian CN, Guo X, Zeng YX, Mai HQ*, Zeng MS*, Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. J Natl Cancer Inst, 2016. 108(1).
    10)Liu ZH, Hu JL, Liang JZ, Zhou AJ, Li MZ, Yan SM, Zhang X, Gao S, Chen L, Zhong Q*, Zeng MS*, Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression. Cell Death Dis, 2015. 6: p. e1920.
    11)Xiong D, Du Y, Wang HB, Zhao B, Zhang H, Li Y, Hu LJ, Cao JY, Zhong Q, Liu WL, Li MZ, Zhu XF, Tsao SW, Hutt-Fletcher LM, Song E, Zeng YX, Kieff E*, Zeng MS*, Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells. Proc Natl Acad Sci U S A, 2015. 112(35): p. 11036-41.
    12)Wang HB, Zhang H, Zhang JP, Li Y, Zhao B, Feng GK, Du Y, Xiong D, Zhong Q, Liu WL, Du H, Li MZ, Huang WL, Tsao SW, Hutt-Fletcher L, Zeng YX, Kieff E, Zeng MS*, Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. Nat Commun, 2015. 6: p. 6240.
    13)Tang LQ, Hu DP, Chen QY, Zhang L, Lai XP, He Y, Xu YX, Wen SH, Peng YT, Chen WH, Guo SS, Liu LT, Qian CN, Guo X, Zeng MS*, Mai HQ*, Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. PLoS One, 2015. 10(4): p. e0122965.
    14)Ni C, Chen Y, Zeng M (co-first author), Pei R, Du Y, Tang L, Wang M, Hu Y, Zhu H, He M, Wei X, Wang S, Ning X, Wang M, Wang J, Ma L, Chen X, Sun Q, Tang H, Wang Y, Wang X*, In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures. Cell Res, 2015. 25(7): p. 785-800.
    15)Zong D, Yin L, Zhong Q, Guo WJ, Xu JH, Jiang N, Lin ZR, Li MZ, Han P, Xu L, He X*, Zeng MS*. ZNF 488 Enhances the Invasion and Tumorigenesis in Nasopharyngeal Carcinoma via the Wnt Signaling Pathway Involving Epithelial Mesenchymal Transition. Cancer Res Treat. 2015 Mar 12. doi: 10.4143/crt.2014.311.
    16)Han P, Lin ZR, Xu LH, Zhong Q, Zhu XF, Liang FY, Cai Q, Huang XM*, Zeng MS*, Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma. Mol Med Rep, 2015. 12(1): p. 401-9.
    17)Tang LQ, Li CF, Chen QY, Zhang L, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Chen WH, Liu H, Guo SS, Liu LT, Li J, Zhang JP, Guo L, Zhao C, Cao KJ, Qian CN, Zeng YX, Guo X, Mai HQ*, Zeng MS*, High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study. Int J Radiat Oncol Biol Phys, 2015. 91(2): p. 325-36.
    18)Feng GK, Liu RB, Zhang MQ, Ye XX, Zhong Q, Xia YF, Li MZ, Wang J, Song EW, Zhang X*, Wu ZZ*, Zeng MS*, SPECT and near-infrared fluorescence imaging of breast cancer with a neuropilin-1-targeting peptide. J Control Release, 2014. 192: p. 236-42.
    19)Yuan L, Liu ZH, Lin ZR, Xu LH, Zhong Q*, Zeng MS*, Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Cancer Biol Ther, 2014. 15(12): p. 1613-21. 
    20)Zhang JP, Zhang H, Wang HB, Li YX, Liu GH, Xing S, Li MZ, Zeng MS*, Down-regulation of Sp1 suppresses cell proliferation, clonogenicity and the expressions of stem cell markers in nasopharyngeal carcinoma. J Transl Med, 2014. 12: p. 222 
    21)Zou QF, Du JK, Zhang H, Wang HB, Hu ZD, Chen SP, Du Y, Li MZ, Xie D, Zou J, Sun HD, Pu JX, Zeng MS* Anti-tumour activity of longikaurin A (LK-A), a novel natural diterpenoid, in nasopharyngeal carcinoma. J Transl Med, 2013. 11: p. 200 
    22)Wang HB, Liu GH, Zhang H, Xing S, Hu LJ, Zhao WF, Xie B, Li MZ, Zeng BH, Li Y, Zeng MS*, Sp1 and c-Myc regulate transcription of BMI1 in nasopharyngeal carcinoma. FEBS J, 2013. 280(12): p. 2929-44.
    23)Xu FH, Xiong D, Xu YF, Cao SM, Xue WQ, Qin HD, Liu WS, Cao JY, Zhang Y, Feng QS, Chen LZ, Li MZ, Liu ZW, Liu Q, Hong MH, Shugart YY, Zeng YX, Zeng MS*, Jia WH*, An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst, 2012. 104(18): p. 1396-410.
    24)Guo BH, Feng Y, Zhang R, Xu LH, Li MZ, Kung HF, Song LB, Zeng MS*, Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer, 2011. 10(1): p. 10.
    25)Kong QL, Hu LJ, Cao JY, Huang YJ, Xu LH, Liang Y, Xiong D, Guan S, Guo BH, Mai HQ, Chen QY, Zhang X, Li MZ, Shao JY, Qian CN, Xia YF, Song LB, Zeng YX, Zeng MS*, Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog, 2010. 6(6): p. e1000940.
    26)Cao JY, Liu L, Chen SP, Zhang X, Mi YJ, Liu ZG, Li MZ, Zhang H, Qian CN, Shao JY, Fu LW, Xia YF*, Zeng MS*, Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Mol Cancer, 2010. 9: p. 237.
    27)Dong J, Zeng BH, Xu LH, Wang JY, Li MZ, Zeng MS*, Liu WL *, Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med, 2010. 8: p. 81.
    28)Liu WL, Guo XZ, Zhang LJ, Wang JY, Zhang G, Guan S, Chen YM, Kong QL, Xu LH, Li MZ, Song LB, Zeng MS*, Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma. BMC Cancer, 2010. 10: p. 467.
    29)Guo BH, Zhang X, Zhang HZ, Lin HL, Feng Y, Shao JY, Huang WL, Kung HF, Zeng MS*, Low expression of Mel-18 predicts poor prognosis in patients with breast cancer. Ann Oncol, 2010. 21(12): p. 2361-9.
    30)Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL, Li MZ, Zhang L, Kang TB, Fu LW, Huang WL, Xia YF, Tsao SW, Li M, Band V, Band H, Shi QH, Zeng YX, Zeng MS*, The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest, 2009. 119(12): p. 3626-36.
    31)Qin ZK, Yang JA, Ye YL, Zhang X, Xu LH, Zhou FJ, Han H, Liu ZW, Song LB, Zeng MS*, Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer, 2009. 9: p. 61.
    32)Liu WL, Zhang G, Wang JY, Cao JY, Guo XZ, Xu LH, Li MZ, Song LB, Huang WL, Zeng MS*, Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun, 2008. 375(3): p. 440-5.
    33)Guo XZ, Zhang G, Wang JY, Liu WL, Wang F, Dong JQ, Xu LH, Cao JY, Song LB, Zeng MS*, Prognostic relevance of Centromere protein H expression in esophageal carcinoma. BMC Cancer, 2008. 8: p. 233.
    34)Liu JH, Song LB, Zhang X, Guo BH, Feng Y, Li XX, Liao WT, Zeng MS*, Huang KH*, Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol, 2008. 97(3): p. 267-72 
    35)Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM, Li MZ, Qin HD, Zeng YX, Zeng MS*, Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res, 2007. 13(2 Pt 1): p. 508-14.
    36)Song LB, Zeng MS*, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V, Zeng YX, Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res, 2006. 66(12): p. 6225-32.
    37)Song LB, Liao WT, Mai HQ, Zhang HZ, Zhang L, Li MZ, Hou JH, Fu LW, Huang WL, Zeng YX, Zeng MS*, The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett, 2006. 242(2): p. 258-65.
    38)Jiang RC, Qin HD, Zeng MS(co-first author), Huang W, Feng BJ, Zhang F, Chen HK, Jia WH, Chen LZ, Feng QS, Zhang RH, Yu XJ, Zheng MZ, Zeng YX*, A functional variant in the transcriptional regulatory region of gene LOC344967 cosegregates with disease phenotype in familial nasopharyngeal carcinoma. Cancer Res, 2006. 66(2): p. 693-700.
    39)Zeng M, Zhang Y, Bhat I, Wazer DE, Band H, Band V*, The human kallikrein 10 promoter contains a functional retinoid response element. Biol Chem, 2006. 387(6): p. 741-7.
    40)Zeng MS, Li DJ, Liu QL, Song LB, Li MZ, Zhang RH, Yu XJ, Wang HM, Ernberg I, Zeng YX*, Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J Virol, 2005. 79(24): p. 15323-30.
    41)Zeng M, Kumar A, Meng G, Gao Q, Dimri G, Wazer D, Band H, Band V*, Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J Biol Chem, 2002. 277(47): p. 45611-8.

    【主要国际学术会议】
    1.大会秘书长:The 6th Guangzhou International Symposium on Oncology, Nov.30-Dec.2, 2017,  Guangzhou, China
    2.特邀会议报告:Title: Cellular Factors in Epstein-Barr Virus Infection of Nasopharyngeal Epithelial Cells, 17th International Symposium on EBV and associated diseases. August 8 to 12, 2016, Zurich, Switzerland
    3.特邀会议报告:Title, NPC, an Epithelial Cancer: Immortalization and Tumorigenesis. NPC Gordon Research Conference, June 26-July 1, 2016, Hong Kong, China
    4.大会秘书长:The 5th Guangzhou International Symposium on Oncology, Dec.1-3, 2016,  Guangzhou, China
    5.特邀会议报告:Title, NPC, The predictive /prognostic biomarker for nasopharyngeal carcinoma. Nasopharyngeal Carcinoma Symposium Biannual Meeting, Jun 3-6, 2015, Yogyakarta, Indonesia
    6.大会秘书长:The 4th Guangzhou International Symposium on Oncology, Nov.5-7, 2015,  Guangzhou, China
    7.特邀会议报告:Title:NRP1 interacts with gB and mediates EBV infection of nasopharyngeal epithelial cells. International Forum for hepesvirus, associated disease and antiviral development. Nov 15-16, 2014  Guangzhou,China
    8.特邀会议报告:Title:Epstein-Barr virus infection in nasopharyngeal carcinoma:Role in pathogenesis and therapeutic implications.Sino-German cancer,viruses and immune response symposium. May 13-14, 2014  Guangzhou,China
    9.受邀参加主题为“代谢异常与肿瘤”的第106期双清论坛  2014.1.7
    10.特邀报告:Nebraska大学特邀中美学术会议  2014.6.11
    11.特邀报告:中德学术研讨会  2014.5.12
    12.受邀参加主题为“上皮细胞可塑性与肿瘤发生发展”的第83期双清论坛  2012.10.31
    13.特邀报告:2012 international Congress on Oncogenic Herpesviruses and Associated Diseases  2012.8.1-8.4
    14.特邀报告:2012年全国肿瘤分子标志学术大会与国际肿瘤转化医学论坛暨第七届中国青年肿瘤专家论坛   2012.7.20-7.23
    15.主题发言:中美头颈肿瘤研讨会2012.1.6-1.7
    16.主题发言:中-法肿瘤学研讨会 2011.11.25-11.26
    17.主题发言: 17th International Charles Heidelberger Symposium on Cancer Research At The Fourth Military Medical University In Xi’an   2011.6.5-6.10
    18.分会报告: The Second Guangzhou International Symposium on Oncology 2011.5.18-5.20
    19.参会并大会发言:Title: Epstein-Barr Virus-Encoded LMP2A Induces EMT and Increases Side Population of Stem-like Cancer Cells in Nasopharyngeal Carcinoma. The 14th Biennial Conference of The International  Association for Research on Epstein-Barr Virus and Associated Diseases  Sept 5-72th ,2010, Birmingham,UK
    20.特邀会议报告:Title:Bmi-1, a polycomb group protein, plays an essential role in tumorigenesis and metastasis. 68th Annual Meeting of the Japanese Cancer Association, Oct 1-3, 2009. Yokohama
    21.特邀会议报告:Title:Bmi-1, a polycomb group protein, plays an essential role in tumorigenesis and metastasis. 2009年6月19日  国际癌症生物研讨会, 国立中山大学生物医学研究所, 高雄
    22.主办并大会报告:The 13th Biennial Conference of The International Association for Research on Epstein - Barr virus and Associated Diseases Nov. 7th— Nov.10th ,2008, 广州。参会代表300余人,包括国外及港台代表 220余人。
    23.特邀大会报告: Title:Cellular and Viral Oncogenes in NP Cell Transformation. AACR International Conference (Infection and Cancer: Biology, Therapeutics, and Prevention) Dec. 5th-7th, 2008. Hongkong
    24.特邀会议报告Title: The mechanism of EBV infection to nasopharyngeal epithelial cells.  The 7th Sino-Japan Joint Conference for Cancer Research December 7th~10th, 2008 Guangzhou, China
    25.参会并大会发言:Title: Bmi-1 is a Novel Molecular Marker of Nasopharyngeal Carcinoma Progression and Immortalizes Primary Human Nasopharyngeal Epithelial Cells.  The 12th Biennial Conference of The International  Association for Research on Epstein-Barr Virus and Associated Diseases  July 8-12th ,2006, Boston
    26.参会并大会发言:Title: Full-length sequencing and analysis of a EBV genome from a Cantonese NPC patient. East-West Symposium on NPC,2005,Toronto, Cannada

    【学术兼职】
    1. 国际EB病毒及相关疾病协会理事会成员(2010-)
    2. 国家自然科学基金委员会专家评审组成员
    3. 中国抗癌协会理事
    4. 中国抗癌协会肿瘤标志专业委员会副主任委员
    5. 中国抗癌协会肿瘤转移专业委员会委员
    6. 广东省预防医学会病毒学专业委员会常务委员
    7. 《癌症》杂志常务篇委
    8、广东省抗癌协会转移委员会主任委员
    9.Scientific Data杂志编委(2014-)


    更新日期:2018年1月24日
访客通道
员工通道
关注肿瘤医院
留言建议 ×